Contract win

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with a new stable Cell Line Development project (the "CLD Project") under a collaborative research and development agreement (the "Agreement") with a US based biotechnology company (the "Client").

Work in relation to the CLD Project is expected to commence shortly and last six to nine months. The Agreement is expected to result in Fusion generating revenues in the region of US$250,000 by the end of 2025.

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to have been selected to generate the definitive cell line for the future production of this important therapeutic product. We look forward to continuing to work with our Client to bring better antibodies to the clinic more rapidly. The CLD Project highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies and their associated cell lines: a part of our offering with excellent scope for growth.

"Whilst it is not anticipated that revenues from the new CLD Project will substantially impact revenues in the current financial year, it provides a valuable bedrock for the financial year ending 31 March 2026. We look forward to continuing to build on the excellent relationship with our Client and to repeating the success with more cell line development projects in the future."